Comparisons of intraocular-pressure-lowering efficacy and side effects of 2% dorzolamide and 1% brinzolamide

Ophthalmologica

Volumn 215, Issue 3, 2001, Pages 188-191

  Seong, Gong Je ^a,c   Lee, Sung Chul ^a   Lee, Jong Hyuck ^b   Chu, Young Kwang ^a   Hong, Young Jae ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University Wonju College of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Brinzolamide; Dorzolamide; Intraocular pressure; Side effects

Indexed keywords

BRINZOLAMIDE; DORZOLAMIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG STRUCTURE; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MALE; PAIN; RANDOMIZED CONTROLLED TRIAL; SLIT LAMP; TONOMETRY; TREATMENT OUTCOME; VISUAL IMPAIRMENT;

ADULT; CARBONIC ANHYDRASE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRAOCULAR PRESSURE; MALE; OPHTHALMIC SOLUTIONS; SAFETY; SULFONAMIDES; THIAZINES; THIOPHENES; TONOMETRY, OCULAR;

EID: 0034983595     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000050856     Document Type: Article

References (24)

1. The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor
2. Comparison of dorzolamide and timolol as suppressors of aqueous humor flow in humans
3. A clinical trial of MK-507 Trusopt, for raised intraocular pressure - The Australian experience
4. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans
5. Clinical efficacy and safety of brinzolamide, a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension
6. Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, Diamox
7. The influence of supplemental sodium acetate on carbonic anhydrase inhibitor-induced side effects
8. Carbonic anhydrase inhibitors
9. Local tolerance and activity of MK927, a novel topical carbonic anhydrase inhibitor
10. MK-927: A topical carbonic anhydrase inhibitor, dose response, and duration of action
11. Multiple-dose dose-response relationship for the topical carbonic anhydrase inhibitor MK-927
12. Multiple-dose efficacy comparison of the two topical carbonic anhydrase inhibitor sezolamide and MK-927
13. A topically effective carbonic anhydrase inhibitor in patients
14. Once daily and twice-daily treatment with the topical carbonic anhydrase inhibitor MK-927
15. A single dose of the topical carbonic anhydrase inhibitor MK-927 decrease IOP in patients
16. MK-507 (L-671,152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkey
17. A study of the in vitro inhibition of human carbonic anhydrase isoenzymes I, II, and IV
18. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor
19. A controlled clinical trial of dorzolamide: A single-centre subset of a multicentre study
20. The additive effect of Trusopt® to beta-blockers in the treatment of glaucoma patients
21. Brinzolamide (AL-4862) suspension is a new topically active carbonic anhydrase inhibitor in the Dutch-belted rabbit and cynomolgus monkey
22. Structure of murine carbonic anhydrase IV and human carbonic anhydrase B complexed with brinzolamide: Molecular basis of isoenzyme-drug discrimination
23. A triple-masked, placebo-controlled, adjunctive study of the efficacy and safety of TID-dosed brinzolamide 1.0% compared to TID-dosed placebo when used adjunctively to timolol 0.5%
24. The ocular comfort of TID-dosed brinzolamide 1.0% compared to TID-dosed dorzolamide 2.0% in patients with primary open-angle glaucoma or ocular hypertension